<DOC>
	<DOCNO>NCT01910610</DOCNO>
	<brief_summary>STRATEGIC-1 study design determine best sequence therapy patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Multi-Line Therapy Trial Unresectable Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This phase III study assess 2 mutli-line therapeutic strategy patient unresectable wild-type RAS metastatic colorectal cancer . All available treatment use strategy ( oxaliplatine , irinotecan , fluoropyrimidines , bevacizumab , cetuximab panitumumab ) different order : STRATEGY A : FOLFIRI-cetuximab , follow oxaliplatin-based chemotherapy bevacizumab vs. STRATEGY B : OPTIMOX-bevacizumab , follow irinotecan-based chemotherapy bevacizumab , follow anti-EGFR mab without irinotecan .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Signed date informed consent , willing able comply protocol requirement , 2 . Histologically proven adenocarcinoma colon and/or rectum , 3 . Wildtype RAS tumor mutation exon 2 [ codon 12/13 ] , exon 3 [ codon 59/61 ] exon 4 [ codon 117/146 ] KRAS NRAS gene ( local assessment , perform either primary tumor metastasis ) , In exceptional circumstance , RAS mutational status ( KRAS NRAS ) pending time randomization , provide obtain within first two cycle first line therapy 4 . Metastatic disease confirm , 5 . No prior therapy metastatic disease ( case previous adjuvant therapy , interval end chemotherapy relapse must &gt; 6 month fluoropyrimidine alone &gt; 12 month oxaliplatinbased , bevacizumabbased , cetuximabbased therapy ) , 6 . Duly document unresectable metastatic disease , ie suitable complete carcinological surgical resection inclusion [ NB : patient unresectable disease study entry potential salvage surgery induction therapy eligible ] , 7 . At least one measurable evaluable lesion assess CTscan MRI ( Magnetic Resonance Imaging ) accord RECIST v1.1 , 8 . Age ≥18 year , 9 . ECOG Performance status ( PS ) 02 , 10 . Hematological status : neutrophil ( ANC ) ≥1.5x109/L ; platelet ≥100x109/L ; haemoglobin ≥9g/dL , 11 . Adequate renal function : serum creatinine level &lt; 150µM , 12 . Adequate liver function : serum bilirubin ≤1.5 x upper normal limit ( ULN ) , alkaline phosphatase &lt; 5xULN , 13 . Proteinuria &lt; 2+ ( dipstick urinalysis ) ≤1g/24hour , 14 . Baseline evaluation perform randomization KRAS WT status know : clinical blood evaluation 2 week ( 14 day ) prior randomization , tumor assessment ( CTscan MRI , evaluation nonmeasurable lesion ) 3 week ( 21 day ) prior randomization , 15 . Female patient must commit use reliable appropriate method contraception trial least six month end study treatment ( applicable ) . Male patient partner childbearing potential must agree use contraception addition partner use another contraceptive method trial least 6 month end study treatment , 16 . Registration national health care system ( CMU include France ) . 1 . History evidence upon physical examination CNS metastasis ( e.g . non irradiate CNS metastasis , seizure control standard medical therapy ) , unless adequately treat , 2 . Exclusive bone metastasis , 3 . Uncontrolled hypercalcemia , 4 . Preexisting permanent neuropathy ( NCI grade ≥2 ) , 5 . Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) , history hypertensive crisis , hypertensive encephalopathy , 6 . Concomitant unplanned antitumor therapy ( e.g . chemotherapy , molecular target therapy , immunotherapy ) , 7 . Treatment investigational medicinal product within 28 day prior study entry , 8 . Other serious uncontrolled nonmalignant disease , 9 . Gilbert 's syndrome , 10 . Other concomitant previous malignancy , except : i/ adequately treat insitu carcinoma uterine cervix , ii/ basal squamous cell carcinoma skin , iii/ cancer complete remission &gt; 5 year , 11 . Major surgery ( open biopsy , surgical resection , wound revision major surgery involve entry body cavity ) significant traumatic injury within last 28 day prior randomization , and/or minor surgical procedure include placement vascular device within 2 day first study treatment , 12 . Pregnant breastfeed woman , 13 . Patients know allergy/hypersensitivity component study drug , 14 . History arterial thrombo and/or embolic event ( e.g . myocardial infarction , stroke , … ) within 6 month prior randomization , 15 . Chronic inflammatory bowel disease 16 . Total bowel obstruction , 17 . History abdominal fistula , GI perforation , intraabdominal abscess active GI bleeding within 6 month prior randomization , 18 . Serious , nonhealing wound , active ulcer untreated bone fracture , 19 . History evidence inherit bleed diathesis significant coagulopathy risk bleeding , 20 . Current recent ( within 10 day randomization ) use aspirin ( &gt; 325 mg/d ) , clopidogrel ( &gt; 75 mg/d ) use oral anticoagulant thrombolytic agent . 21 . Concomitant administration live , attenuated virus vaccine yellow fever vaccine 22 . Concomitant administration prophylactic phenytoin . 23 . Treatment sorivudine chemically related analogue , brivudine . 24 . Patients know dihydropyrimidine dehydrogenase ( DPD ) deficiency . 25 . Concomitant use St John 's Wort 26 . Patients interstitial pneumonitis pulmonary fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>wild-type RAS metastatic colorectal cancer</keyword>
</DOC>